TREATMENT OF RETINOPATHIES USING GFRa3 AGONISTS

摘要

The present invention relates to the use of GFRa3 agonists for the treatment of disorders of the retina. A preferred GFRa3 agonist is Neublastin. Neublastin may be administered to the eye using protein formulations, in vivo or ex vivo gene therapy, or implantation of encapsulated cells delivering Neublastin locally to the retina.